CME on the Go—A Primary Care Look at Substances with Abuse Potential

Source: American Academy of Family Physicians

In this episode of CME On the Go, the hosts discuss the integration of psychedelic substances like ketamine, psilocybin, iboga, and various social stimulants into treatment practices. The conversation delves into the therapeutic potential and risks associated with these substances, particularly for treatment-resistant conditions like depression and opioid addiction. The hosts emphasize the importance of setting, intention, and evidence-based practice while navigating the emerging landscape of psychedelics in medicine.

1. 1. Examine the emerging evidence on therapeutic uses and risks of substances like psilocybin, ketamine, and other quasi-illicit drugs, while recognizing historical and cultural influences on their stigma.
   2. Discuss strategies for counseling patients about the actual versus perceived risks of these substances, including legal, safety, and harm reduction considerations.
   3. Recognize the impact of regional attitudes and biases on clinician-patient conversations around quasi-illicit substances and develop approaches to foster open, nonjudgmental dialogue.

After listening to the podcast episode, claim 0.5 American Academy of Family Physicians continuing medical education credits.